Burning Rock Biotech Ltd (BNR)

NASDAQ
3.52
-0.15(-4.09%)
  • Volume:
    189,582
  • Day's Range:
    3.49 - 3.61
  • 52 wk Range:
    1.74 - 22.22

BNR Overview

Prev. Close
3.67
Day's Range
3.49-3.61
Revenue
78.74M
Open
3.6
52 wk Range
1.74-22.22
EPS
-1.27
Volume
189,582
Market Cap
370.26M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
784,934
P/E Ratio
-
Beta
-
1-Year Change
-81.35%
Shares Outstanding
105,188,102
Next Earnings Date
Aug 22, 2022
What is your sentiment on Burning Rock?
or
Market is currently closed. Voting is open during market hours.

Burning Rock Biotech Ltd Analysis

Burning Rock Biotech Ltd Company Profile

Burning Rock Biotech Ltd Company Profile

Employees
1394

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellStrong SellSellSell
Technical IndicatorsStrong SellStrong SellStrong SellBuyStrong Sell
SummaryStrong SellStrong SellStrong SellNeutralStrong Sell
  • why no one here
    0
    • why no one here
      0